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Abstract
Background: The common cytotoxic mechanisms that un-
derpin chemoefficacy and toxicity have hampered efforts to 
deliver effective supportive care interventions, particularly 
for gastrointestinal (GI) toxicity. Matrix metalloproteinases 
(MMPs) have been implicated in both tumor growth and GI 
toxicity, and as such MMP inhibitors present as a novel ther-
apeutic avenue to simultaneously enhance treatment effi-
cacy and reduce toxicity. Objectives: The aim of this study 
was to determine the efficacy of an MMP-9/12 inhibitor, 
AZD3342, on tumor growth and GI toxicity in a rat model. 
Methods: Female tumor-bearing Dark Agouti rats (n = 90) 
were divided into 4 groups: vehicle control; methotrexate 
(MTX); AZD3342, and MTX + AZD3342. Tumors were mea-
sured daily (for 5 days) using digital calipers. GI toxicity was 
assessed using well-established clinical markers (diarrhea/
weight loss), histopathological analysis, and functional as-
sessment of intestinal barrier permeability. Results: AZD3342 
delayed the onset of severe diarrhea by 1 day (vs. MTX) but 
was unable to improve the overall severity of diarrhea. No 
changes were detected in tissue morphology or intestinal 
barrier function. AZD3342 alone suppressed tumor growth 
(p = 0.003 vs. vehicle) but did not enhance the efficacy of 
MTX. Conclusions: This study showed partial efficacy of 
AZD3342 in reducing tumor growth and delaying the onset 
of severe diarrhea caused by MTX in rats. We suggest further 
studies be undertaken targeting appropriate scheduling of 
AZD3342 as well as investigating different cytotoxic thera-
pies that strongly activate MMP signaling.
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Introduction
The common cytotoxic mechanisms underpinning 
both the efficacy and toxicity of chemotherapy have hin-
dered efforts to deliver effective supportive care mea-
sures. This is particularly the case for the management 
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of chemotherapy-induced gastrointestinal (GI) toxicity, 
with dysregulated cytotoxicity and inflammation at the 
core of its pathobiology. GI toxicity affects between 40 
and 100% of patients with cancer treated with chemo-
therapy [1]. Manifesting as diarrhea, pain, and rectal 
bleeding, GI toxicity has a significant impact on quality 
of life, rendering patients housebound due to embarrass-
ment, fatigue, pain, or simply the fear of needing to def-
ecate suddenly. In severe cases, it requires hospitalization 
and extensive supportive care measures, which can result 
in chemotherapy dose reductions/delays or complete 
treatment cessation [2]. In addition, severe GI toxicity 
predisposes to infectious complications and places pa-
tients at a 4-fold higher risk of treatment-related death. 
The management of these complications requires exten-
sive supportive care measures, increasing the length of 
hospitalization and contributing to the growing econom-
ic burden associated with cancer therapy [3]. 
Currently, GI toxicity cannot be accurately predicted 
and is without an effective intervention [2]. As such, the 
identification of novel therapeutic targets that do not 
compromise treatment efficacy is critical to improve the 
management of this significant oncological challenge. 
Matrix metalloproteinases (MMPs) are a group of zinc-
dependent endopeptidases involved in extracellular ma-
trix homeostasis [4]. We have previously shown that 
MMPs are upregulated in the gut in a number of preclin-
ical models of chemotherapy-induced GI toxicity [5, 6]. 
We have also confirmed these findings in a clinical co-
hort, with upregulated MMP concentrations in the serum 
of patients treated with standard dose chemotherapy for 
breast and colorectal cancer [7]. These findings are of 
clinical importance as MMP inhibitors have been inves-
tigated for their anti-tumor activity, both alone and in 
combination with chemotherapy [8, 9], with data sug-
gesting they may be a valid adjunct to traditional cancer 
care. Despite this, the effect of MMP inhibition on GI 
toxicity and tumor kill are yet to be investigated in paral-
lel. As such, paralleled investigation of MMP inhibition 
on treatment toxicity and efficacy presents as a novel 
therapeutic approach.
AZD3342 is a 403 D synthetic inhibitor of MMP-8, 
MMP-9, and MMP-12, with greatest affinity for MMP-9 
and MMP-12 [10]. While AZD3342 has demonstrated 
preclinical efficacy in the repair of colonic injury, it has 
primarily been studied for its therapeutic potential in 
chronic obstructive pulmonary disease [10]. For the pre-
vention of preclinical GI toxicity and paralleled impact on 
chemoefficacy, AZD3342 is an attractive agent due to its 
narrow spectrum of MMP inhibition, and thus reduced 
likelihood of adverse toxicity, a common finding in nu-
merous clinical trials using broad-acting MMP inhibitors 
[9, 11]. Its affinity for MMP-9 and MMP-12 also holds 
therapeutic potential as these have both been implicated 
in the pathobiology of GI toxicity. This is particularly the 
case for MMP-9, which has been shown to increase in the 
gut following preclinical irinotecan [6, 12], as well as sys-
temically in patients undergoing standard dose chemo-
therapy [7]. In the case of cancer progression, a number 
of MMPs have been implicated in cancer progression, in-
vasion, and metastasis, including MMP-2, 9, 11, 12, and 
14 [13, 14], with altered expression/activity in the tumor 
microenvironment, as well as MMP polymorphisms 
linked with increased susceptibility to various malignan-
cies [15, 16]. As such, the aim of the current study was to 
investigate the efficacy of selective MMP inhibition, using 
AZD3342, on the prevention of GI toxicity while simul-
taneously assessing tumor burden. 
Materials and Methods
This study is reported using the ARRIVE guidelines for the ac-
curate and reproducible reporting of animal research. 
Ethical Statement and Husbandry Specifications
All animal studies were conducted in accordance with ethics 
approved by the Animal Ethics Committee at the University of 
Adelaide and complied with the National Health and Medical Re-
search Council (Australia) Code of Practice for Animal Care in 
Research and Teaching (2013). Animals were individually housed 
in conventional, open cages at the Laboratory Animal Sciences Fa-
cility of the University of Adelaide. Rats were housed under a 12-h 
light/dark cycle with ad libitum access to autoclaved standard ro-
dent pellets and sterile water. Sawdust bedding was provided in all 
cases, as well as crinkle paper and toilet rolls for enrichment. All 
cages were randomly arranged across racks to prevent potential 
biases. 
Study Design 
GI toxicity and the tumoricidal properties of MMP inhibition 
were assessed in a tumor-bearing (mammary adenocarcinoma) 
rat model. Female dark agouti rats weighing 150–170 g (7–9 weeks 
in age) were used for all experiments. All rats were subcutane-
ously inoculated with 0.2 mL (2.0 × 107 cells/mL) mammary ad-
enocarcinoma cells on each flank. Tumors were allowed to form 
until they reached approximately 1% of total body weight (ap-
proximately 1 week). Rats were then randomly allocated into con-
trol or experimental groups: vehicle control (2% Avicel solu-
tion/0.5% Tween 80, n = 18); AZD3342 (kindly supplied by Astra-
Zeneca, n = 18); MTX (n = 18), and AZD3342 + MTX (n = 36). 
Randomization was performed using unblinded randomized 
number generation in Excel. Minor adjustments were made to 
ensure experimental groups exhibited comparable baseline body 
weight and tumor size. 
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Drugs: MTX and AZD3342 
Methotrexate (MTX, Sigma-Aldrich) was used as a represen-
tative chemotherapeutic agent for treatment of breast cancer. 
The dose of MTX was based on those used in previous cyclic 
models of GI toxicity in which clinically relevant weight loss and 
self-limiting diarrhea were observed [17]. AZD3342 (AstraZen-
eca) is a 403 D synthetic selective MMP inhibitor targeting MMP-
8, 9, and 12. Previous reports indicate higher inhibitory capacity 
for MMP-9 and MMP-12, with IC50 values of 16 nM (MMP-8), 
10 nM (MMP-9), and 6 nM, (MMP-12) [10]. Previous research 
has shown that three consecutive subcutaneous doses of 50 mg/
kg is sufficient to increase anastomosis breaking strength and re-
duce leakage. For maximal contact with the intestinal epithelium, 
AZD3342 was administered via oral gavage (p.o.) twice daily for 
3 days [10]. Due to the targeted luminal exposure and higher fre-
quency of administration, a dose of 20 mg/kg was selected for all 
experiments. 
Induction of GI Toxicity 
MTX was administered under 3% isofluorane anesthetic twice 
(day 0 and day 1; 9 a.m.) at 2 mg/kg (6.25 mg/mL) intramuscu-
larly. Control rats received saline injections in an equivalent vol-
ume. AZD3342 or vehicle control (2% Avicel solution/0.5% Tween 
80) was administered via oral gavage (20 mg/kg, 4 mg/mL) twice 
daily (9 a.m. and 5 p.m.) beginning on day –1 and ending after the 
final MTX injection (day 1; Fig. 1). Groups of rats were killed via 
isoflurane anesthesia, cardiac puncture, and cervical dislocation at 
24, 48, 72, 96, and 120 h after the first dose of MTX.
All procedures were performed in designated procedure rooms 
within the Laboratory Animal Sciences Facility at the University of 
Adelaide. The primary outcome of the study was GI toxicity, de-
fined by body weight loss. Secondary outcomes included diarrhea 
incidence and severity, intestinal injury as determined by histopa-
thology, intestinal barrier function, and tumor burden. 
GI Toxicity Assessment 
All rats were monitored twice daily for the presence of diarrhea. 
Two independent assessors (A.W. and J.S.) quantified diarrhea us-
ing a validated grading system where 0 = no diarrhea, 1 = mild 
diarrhea with soft stools and perianal staining, 2 = moderate diar-
rhea with loose stools and perianal staining of fur, 3 = severe diar-
rhea with watery stools with or without mucous, and fur staining 
incorporating the hind legs [18]. In addition, rats were weighed 
daily to track weight loss/gain. Body weight was corrected for tu-
mor weight. Rats were euthanised if they displayed > 15% weight 
loss or significant distress and deterioration, in compliance with 
animal ethical requirements. Assessments were performed at the 
same time daily (10 a.m. and 3 p.m.) to mitigate potential biases 
relating to circadian rhythms. 
Ex vivo Intestinal Permeability Assessment 
Intestinal permeability was assessed using 4 kDa fluorescein 
isothiocyanate (FITC)-dextran (Sigma-Aldrich). All rats re-
ceived a 600 mg/kg dose (120 mg/mL) of 4 kDa FITC-dextran via 
oral gavage 2 h prior to culling. Blood was then collected via car-
diac puncture at necropsy into serum-gel clotting activator tubes 
and protected from light. Samples were centrifuged at 3,000 rpm 
for 10 min and serum isolated. Serum samples were diluted 1: 3 
with 1 × PBS and quantified using the BioTek Synergy® Mx Mi-
croplate Reader (BioTek, Winooski, VT, USA) and Gen5 version 
2.00.18 software relative to a standard curve (range 0.0001–10 µg/
mL). 
Histopathological Analysis: Tissue Preparation
At necropsy, the entire GI tract from the pyloric sphincter to 
rectum was dissected and flushed with chilled isotonic saline to 
remove intestinal contents. Samples of jejunum and colon were 
collected and fixed in 10% formalin for embedding in paraffin. All 
histopathological analysis was conducted on 5-µm sections cut on 
a rotary microtome and mounted onto glass Superfrost® micro-
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Fig. 1. Experimental timeline. Tumor-bearing rats were randomized to receive vehicle control, AZD3342 alone, 
MTX + AZD3342 vehicle, or MTZ + AZD3342. MTX was delivered in two intramuscular doses of 2 mg/kg. 
AZD3342 was administered twice daily (20 mg/kg) on 3 consecutive days via oral gavage. Rats were euthanized 
at 24, 48, 72, 96, and 120 h after the first MTX injection. 




scope slides (Menzel-Gläser, Braunschweig, Germany). Slides 
were scanned using a NanoZoomer® (Hamamatsu Photonics, Ja-
pan) and assessed with NanoZoomer Digital Pathology software 
view.2 (Histalim, Montpellier, France).
Hematoxylin and Eosin Staining and Analysis 
Hematoxylin and eosin staining was performed on the jejunum 
and colon. A total tissue injury score was generated using a vali-
dated grading system based on the occurrences of eight histologi-
cal criteria in the jejunum, and six criteria in the colon [19, 20]. 
These criteria were villous fusion and villous atrophy (jejunum 
only), disruption of brush border and surface enterocytes, crypt 
loss/architectural disruption, disruption of crypts cells, infiltration 
of polymorphonuclear cells and lymphocytes, dilation of lymphat-
ics and capillaries, and edema. Each parameter was scored as ab-
sent = 0, present = 1, severe = 2 in a blinded fashion.
Tumor Assessment 
Tumors were measured daily using digital calipers. Tumor bur-
den was calculated as tumor length (width)2 × ∏/6 and expressed 
relative to body weight (%).
Statistical Analysis 
All data were assessed for normality using the D’Agostino-
Pearson normality test in GraphPad Prism (v.7). In cases of nor-
mality, a two-way analysis of variance (ANOVA) with Tukey’s 
post hoc test was used. Nonparametric data were analyzed using a 




In accordance with the ARRIVE guidelines, baseline 
characteristics of each experimental group were analyzed 
at –24 h, prior to the first AZD3342 administration (Table 
1). There were no statistically significant differences in 
body weight or tumor burden between the groups. 
Clinical Assessment of GI Toxicity 
Clinical parameters of intestinal injury include diar-
rhea, weight loss, and intestinal barrier dysfunction. Con-
trol rats (vehicle control and AZD3342 alone) did not dis-
play clinical markers of GI injury (data not shown). Rats 
were assessed twice daily for diarrhea severity, with the 
highest severity of that day used for statistical analysis and 
presentation. All rats treated with MTX experienced diar-
rhea (Fig. 2a, b). Rats that received only MTX had grade 
3 diarrhea commencing 48 h after MTX (Fig. 2a). In con-
trast, rats treated with MTX + AZD3342 had a delay in 
severe diarrhea which commenced 72 h after MTX 
(Fig. 2b). The incidence and severity of diarrhea was sim-
ilar from 72 h onwards across groups treated with MTX 
and MTX + AZD3342. 
MTX caused severe weight loss in all animals. 
AZD3342 was unable to prevent MTX-induced changes 
in weight loss (mean ± SEM: MTX, –13.01 ± 2.3%; 
MTX + AZD, –12.82 ± 1.73%; Fig. 2c). Similarly, no sig-
nificant difference in intestinal barrier dysfunction de-
fined by serum FITC-dextran concentration was identi-
fied between MTX and MTX + AZD animals (mean ± 
SEM: MTX, 4.6 ± 0.16 µg/mL; MTX + AZD, 2.72 ± 0.76 
µg/mL; Fig. 2d). 
Histopathological Assessment 
MTX injury in both groups and was characterized by 
severe villous atrophy with stunting and fusion of villi, 
and crypt disruption in the jejunum (Fig. 3). In the con-
gested lamina propria there was an increased inflamma-
tory infiltrate comprised of lymphocytes, macrophages, 
plasma cells, and neutrophils, and dilatation of lacteals 
(Fig. 3a). MTX induced small intestinal atrophy, indi-
cated by wet weights measured at necropsy (Fig.  3b). 
This remained statistically significant until 96 h. Rats 
treated with MTX had significantly increased injury 
scores in the jejunum compared to controls at both 48 
and 96 h (p < 0.01; Fig. 3c). There were no differences in 
injury score at any time point in the colon (data not 
shown). 
Tumor Burden
Tumor growth as a percentage of body weight was 
measured daily. Rats began treatment with either vehicle 
control or AZD3342 when tumors were approximately 
1% of body weight. Over the time course of the experi-
ment, rats treated with only AZD3342 had significantly 
smaller tumors at 72 h (mean ± SEM: 5.5 ± 0.40%, p = 
0.003) than vehicle controls (7.4 ± 0.52%; Fig. 4a). This 
effect was not maintained at necropsy, with only rats 
treated with MTX or MTX + AZD3342 showing a sig-
nificant reduction in tumor weight from 72 h onwards 
(Fig. 4b). 
Table 1. Baseline body weight and tumor burden in each experi-
mental group
Body weight, g Tumor size, cm3
Vehicle (n = 18) 160.47±1.78 0.68±0.08
AZD3342 (n = 18) 158.57±2.63 0.63±0.06
MTX (n = 18) 157.90±2.28 0.61±0.05
MTX + ADZ3342 (n = 36) 159.25±2.05 0.61±0.03 
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Discussion
There is currently an unmet need to effectively manage 
GI toxicity without impacting chemoefficacy. MMPs 
present a promising therapeutic target due to their emerg-
ing role in both tumor development and GI inflamma-
tion, both of which stem from their regulation and de-
struction of the extracellular matrix. The current study 
therefore investigated the potential dual action of an 
MMP inhibitor, AZD3342, in reducing tumor burden 
and GI toxicity caused by MTX. 
Despite a growing body of preclinical and clinical re-
search implicating MMPs in the development of GI in-
jury, the current study only found modest benefits of 
AZD3342 in delaying severe diarrhea. AZD3342 did not 
protect against MTX-induced intestinal barrier dysfunc-
tion, weight loss, or histopathological injury. These find-
ings are consistent with previous research showing MMP 
inhibition with doxycycline was unable to attenuate che-
motherapy-induced oral mucositis [21]. They are, how-
ever, inconsistent with a growing body of evidence impli-
cating MMPs in intestinal inflammation and demonstrat-
ed efficacy of MMP inhibition. Our study also indicated 
no clinically relevant impact on tumor development 
when MTX was administered in combination with 
AZD3342. Although AZD3342 alone reduced tumor size 
at 72 h, this protection did not translate to other time 
points and was not observed in the presence of MTX. This 
highlights the inability of this compound, in this particu-
lar preclinical model, to adequately impact on tumor pro-
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Fig. 2. Clinical markers of GI toxicity. a Rats treated with MTX 
developed severe diarrhea from 48 h. b Severe diarrhea was not 
seen until 72 h in rats treated with MTX + AZD3342. AZD3342 
did not reduce the severity of MTX-induced diarrhea from 72 h. 
AZD3342 did not prevent MTX-induced weight loss (c) or intes-
tinal barrier dysfunction (d). Diarrhea data are shown as percent-
age of animals experiencing grade 0–3 diarrhea. Weight loss and 
serum FITC-dextran data are shown as the mean ± SEM and were 
analyzed using a two-way ANOVA with Tukey’s post hoc test. 




gression when used in isolation and as an adjunct to che-
motherapy. 
Clinically, there are conflicting data regarding the ef-
ficacy and safety of adjunctive MMP inhibition in cancer 
treatment. For example, Heath et al. [8] reported reduced 
tumor growth and spread in patients with a variety of sol-
id tumors treated with the MMP inhibitor BAY12-9566 in 
combination with routine anti-cancer treatment. Howev-
er, in initial phase I dose-finding studies, significant ad-
verse toxicity was observed, including anemia, shoulder/
back pain, liver abnormalities, nausea, fatigue, diarrhea, 
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Fig. 3. Intestinal injury assessment. a Representative photomicro-
graphs of the jejunum (original magnification, ×100). Arrows in-
dicate crypt loss (filled arrows), surface enterocyte loss and villous 
blunting (open arrows), and inflammatory infiltrate (arrowhead). 
b Small intestinal wet weights indicate MTX-induced atrophy. 
AZ3342 did not prevent MTX-induced small intestinal atrophy. 
c Histological damage scoring in the jejunum shows a significant 
increase in injury in groups treated with MTX. AZD3342 did not 
prevent MTX-induced injury (p = ns). No changes were seen in 
tissue injury scores for the colon (data not shown). Data are shown 
as the mean ± SEM; * p < 0.05 versus vehicle control, # p < 0.05 
versus AZD3342 control. All data were analyzed using a two-way 
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grade III or were considered dose limiting. These findings 
are in contrast to those of Leighl et al. [9] reporting more 
frequent and severe adverse events (rash, hypersensitivity 
reactions, and febrile neutropenia) and no improvements 
in overall survival in patients with advanced non-small 
cell lung cancer co-treated with the broad-spectrum MMP 
inhibitor, BMS-275291. It has been speculated that toxici-
ties associated with adjunctive MMP inhibition likely re-
sult from specific drug-drug interactions and dysregulat-
ed balance between MMP and their natural inhibitory 
partners, TIMPs (tissue inhibitors of metalloproteinases). 
This parallels concerns raised in another study using the 
same broad-acting inhibitor in patients with breast and 
prostate cancer. In this small phase II trial, increased rates 
of musculoskeletal toxicity were seen in the experimental 
arm of the study, with these patients also more susceptible 
to grade 3 rash and dose-reductions/cessation. These re-
ports highlight the need to pursue MMP inhibition as an 
adjunct to traditional cancer therapy with extreme cau-
tion, with more detailed preclinical investigation. 
Given the lack of overwhelming benefit observed clin-
ically for MMP inhibition, the results of the current pre-
clinical study remain difficult to interpret. They are in 
stark contrast to what has been demonstrated in previous 
preclinical research, however appear to reflect the lack of 
efficacy seen clinically. In any case, the results of our study 
need to be considered within the landscape of our par-
ticular preclinical model. Firstly, the dosing schedule 
chosen for AZD3342 may not have been most beneficial. 
Given that our previously published data have shown 
some MMP subtypes maximally increase at 48 h follow-
ing cytotoxic therapy [12], further investigations into 
AZD3342 should test extended therapy protocols that in-
corporate exposure both before MTX and continuously 
after MTX to provide maximum coverage. Secondly, the 
profile of MTX-induced MMP upregulation is not as well 
characterized compared to that of other chemotherapeu-
tic agents, specifically irinotecan [6, 12]. While MTX was 
an attractive agent to use in our model due to its mam-
mary adenocarcinoma target, further investigation of 
AZD3342 is warranted in preclinical models using other 
different cytotoxic therapies that strongly activate MMP 
signaling. MTX dosing schedules may also need to be re-
vised to induce a less severe diarrhea phenotype. It is pos-
sible that the severity of mucosal injury observed in this 
study was so profound that it may have masked any po-
tential benefits of AZD3342. Alternatively, the lack of 
clinical benefit seen in our study may reflect the inability 
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Fig. 4. Tumor growth over 120 h. a MTX and MTX + AZD3342 
inhibited tumor size compared to vehicle control and AZD3342 
alone. A significant reduction in tumor size was seen at 72 h 
between AZD3342 alone and vehicle control (**  p = 0.003). 
b Reduced tumor weight was seen in rats treated with MTX and 
MTX + AZD3342 compared to vehicle control but no differences 
between MTX and MTX + AZD3342 were found. This effect was 
seen at 72 h (MTX vs. vehicle, * p = 0.001; MTX + AZD3342 vs. 
vehicle, * p = 0.0003), 96 h (MTX vs. vehicle, * p < 0.0001; MTX vs. 
AZD3342, # p = 0.0002; MTX + AZD3342 vs. vehicle, * p < 0.0001; 
MTX + AZD3342 vs. AZD3342, # p < 0.0001), and 120 h (MTX vs. 
vehicle, *  p < 0.0001; MTX vs. AZD3342, #  p < 0.0001; MTX + 
AZD3342 vs. vehicle, * p < 0.0001; MTX + AZD3342 vs. AZD3342, 
# p < 0.0001). All data were analyzed using a two-way ANOVA with 
Tukey’s post hoc test. Data are presented as the mean ± SEM.




of AZD3342 to effectively inhibit MMPs involved in GI 
toxicity development. Given that we did not directly as-
sess this in our study, the targeted efficacy of AZD3342 in 
our model remains unclear.
In conclusion, AZD3342 was not effective at reducing 
overall MTX-induced GI toxicity and had only a modest 
impact on mammary adenocarcinoma growth in the 
Dark Agouti rat. However, given the short delay seen in 
the onset of severe diarrhea and jejunal tissue injury, we 
suggest further studies be undertaken to assess the effi-
cacy of AZD3342 in preventing GI toxicity using different 
cytotoxic therapies that strongly activate MMP signaling. 
In all future experiments, detailed investigation in tumor-
naïve and tumor-bearing rats should be performed to dis-
sect the potential of MMP inhibition in GI toxicity and to 
determine the impact of tumor kinetics on this mecha-
nism. This will enable more insightful results to be 
achieved regarding the origins of adverse toxicities. 
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